Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for RSV Disease Aged 18 to 59 Years

Journal:

Clinical Infectious Diseases

Published:

2025-06-04

DOI:

10.1093/cid/ciaf292

Affiliations:

6

Authors:

21

Go to article

Institutions	Authors	Share
Moderna, United States of America (USA)	16.000000 16.000000	0.76
University of Rochester (UR), United States of America (USA)	1.000000	0.05
Layton Medical Centre, United Kingdom (UK)	1.000000	0.05
Colchester Research Group, Canada	1.000000	0.05
Indago, United States of America (USA)	1.000000	0.05
Cambridge ID & Immunology Consulting, LLC, United States of America (USA)	1.000000	0.05

Interested in Medical Microbiology?